Cargando…
Responder analysis for improvement in 6‐min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency
AIM: Improving functional capacity is a key goal in heart failure (HF). This pooled analysis of FAIR‐HF and CONFIRM‐HF assessed the likelihood of improvement or deterioration in 6‐min walk test (6MWT) among iron‐deficient patients with chronic HF with reduced ejection fraction (HFrEF) receiving ferr...
Autores principales: | Anker, Stefan D., Ponikowski, Piotr, Khan, Muhammad Shahzeb, Friede, Tim, Jankowska, Ewa A., Fabien, Vincent, Goehring, Udo‐Michael, Metra, Marco, Piña, Ileana L., Coats, Andrew J.S., Rosano, Giuseppe, Dorigotti, Fabio, Comin‐Colet, Josep, Van Veldhuisen, Dirk J., Filippatos, Gerasimos S., Butler, Javed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321075/ https://www.ncbi.nlm.nih.gov/pubmed/35334136 http://dx.doi.org/10.1002/ejhf.2491 |
Ejemplares similares
-
Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency
por: Butler, Javed, et al.
Publicado: (2022) -
Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced
por: Ferreira, João Pedro, et al.
Publicado: (2022) -
Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long‐term extension data from a Phase 3 study
por: Schmidt, C., et al.
Publicado: (2016) -
Effect of ferric carboxymaltose on calculated plasma volume status and clinical congestion: a FAIR‐HF substudy
por: Okonko, Darlington O., et al.
Publicado: (2019) -
Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial
por: Metra, Marco, et al.
Publicado: (2022)